Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094790 | 1.00 | TACR1 (1.00) | TACR1TACR2 | |
| SCHEMBL31061161 | 1.00 | TACR1 (1.00) | TACR1TACR2 | |
| SCHEMBL7462043 | 0.89 | TACR2 (1.00) | TACR1TACR2 | |
| SCHEMBL7814154 | 0.86 | TACR1 (1.00) | TACR1TACR2 | |
| SCHEMBL7814157 | 0.86 | TACR1 (1.00) | TACR1TACR2 | |
| SCHEMBL7804677 | 0.85 | TACR1 (1.00) | TACR1TACR2 | |
| SCHEMBL3083322 | 0.84 | TACR2 (1.00) | TACR1TACR2 | |
| SCHEMBL3083325 | 0.84 | TACR2 (1.00) | TACR1TACR2 | |
| Trifluoroacetic Acid SCHEMBL8472654 | 0.84 | TACR1 (0.87) | TACR1TACR2 | |
| SCHEMBL6979016 | 0.83 | TACR1 (0.72) | TACR1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090795-A1 | Pharmaceutical Compositions Based on Nk2 Antagonists for Pediatric Use | LABORATORI GUIDOTTI S.P.A. (IT) | 2008-04-17 | — | — | US | claimed |
| EP-1809267-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON NK2 ANTAGONISTS FOR PEDIATRIC USE | Laboratori Guidotti S.P.A. (IT) | 2007-07-25 | — | — | EP | claimed |
| WO-2006045820-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON NK2 ANTAGONISTS FOR PEDIATRIC USE | LABORATORI GUIDOTTI S.P.A. (IT) | 2006-05-04 | — | — | WO | claimed |
| CN-113461599-B | Process for preparing piperidone compounds | 南方科技大学 | 2024-02-09 | — | — | CN | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| CN-114206849-A | Therapeutic methods for treating non-infectious ocular immunoinflammatory disorders | 斯格本斯眼科研究所有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-9556200-B2 | Tricyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-2824106-B1 | TRICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-20150045351-A1 | TRICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-12 | — | — | US | disclosed |
| EP-2824106-A1 | TRICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-01-14 | — | — | EP | disclosed |
| US-20100234284-A1 | Pharmaceutical compositions based on NK2 antagonists for pediatric use | ALEOTTI ALBERTO | 2010-09-16 | — | — | US | disclosed |
| US-7727955-B2 | Pharmaceutical compositions based on NK2 antagonists for pediatric use | LABORATORI GUIDOTTI S.P.A. (IT) | 2010-06-01 | — | — | US | disclosed |
| US-20080090795-A1 | Pharmaceutical Compositions Based on Nk2 Antagonists for Pediatric Use | LABORATORI GUIDOTTI S.P.A. (IT) | 2008-04-17 | — | — | US | disclosed |
| EP-1809267-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON NK2 ANTAGONISTS FOR PEDIATRIC USE | Laboratori Guidotti S.P.A. (IT) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006045820-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON NK2 ANTAGONISTS FOR PEDIATRIC USE | LABORATORI GUIDOTTI S.P.A. (IT) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045351-A1 | TRICYCLIC COMPOUND | HTR2C, HTR1A, HTR2A | TACR1 47/4885TACR2 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.